Carboplatin News and Research

RSS

Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).

AstraZeneca receives positive NICE recommendations for lung cancer treatment

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across England and Wales.

25 Jan 2025

Research finds no change in mortality despite platinum chemotherapy shortage

During a shortage of the generic platinum chemotherapy drugs cisplatin and carboplatin that began in early 2023, there was no difference in mortality rates among patients with advanced cancer compared to the previous year, and prescription rates for the two drugs fell less than three percent overall - and 15.1 percent at the peak - according to an analysis published this week in the Journal of the National Cancer Institute by researchers from the University of Pennsylvania's Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

14 Dec 2024

Metabolic imaging detects ovarian cancer subtypes and predicts chemotherapy response

Study demonstrates how metabolic imaging differentiates high and low oxidative phosphorylation (OXPHOS) subtypes of high-grade serous ovarian cancer (HGSOC). By assessing metabolic activity, it also identifies early and variable responses to chemotherapy, improving precision in treatment strategies.

10 Dec 2024

MRI-based imaging technique predicts the response of ovarian cancer to treatment

An MRI-based imaging technique developed at the University of Cambridge predicts the response of ovarian cancer tumors to treatment, and rapidly reveals how well treatment is working, in patient-derived cell models.

6 Dec 2024

Cetuximab performs better than durvalumab in treating head and neck cancers

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report. Smokers and drinkers, as well as those with HPV infections, are disproportionately affected.

22 Nov 2024

VANCE trial marks milestone in t cell therapy for solid tumors

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell therapy.

11 Nov 2024

New combination treatment authorized for unresectable urothelial cancer patients

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy.

18 Oct 2024

Short course chemotherapy boosts survival rates in cervical cancer patients

Cervical cancer patients were significantly more likely to be alive and cancer-free after five years when given a short course of chemotherapy prior to chemoradiation, finds a clinical trial led by researchers from UCL and UCLH.

15 Oct 2024

Pre-surgery chemotherapy shows promise for preserving vital organs in nasal and sinus cancer

Results from a clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) show a striking improvement for patients who received chemotherapy before surgery to remove advanced squamous cell-type cancer of the nose or sinus.

11 Sep 2024

Long-term effects of chemotherapy on hearing and quality of life in testicular cancer survivors

An interdisciplinary study led by researchers at the University of South Florida and Indiana University has uncovered significant findings on the long-term effects of one of the most common forms of chemotherapy on cancer survivors.

28 Jun 2024

NCCN survey reveals ongoing shortages in crucial cancer medications

The National Comprehensive Cancer Network (NCCN) - a nonprofit alliance of leading cancer centers - is publishing new results for its latest survey on cancer drug shortages in the United States.

26 Jun 2024

New recommendations for radiation therapy in HPV-associated oropharyngeal cancer

A multi-disciplinary task force convened by the American Society for Radiation Oncology has issued new guidelines for radiation therapy for HPV-associated oropharyngeal squamous cell carcinoma (OPSCC).

18 Jun 2024

Sacituzumab govitecan plus platinum-based chemotherapy effective in multiple carcinomas

A new research paper was published in Oncotarget's Volume 15 on February 22, 2024, entitled, "Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas."

5 Mar 2024

New method traces primed resistance in cancer via sister cells

In many cancers, such as ovarian cancer, each round of chemotherapy kills the majority of cancer cells, while a small population of them survives through treatment.

12 Feb 2024

A certain type of chemotherapy found to improve the immune system's ability to fight off bladder cancer

Tisch Cancer Institute researchers discovered that a certain type of chemotherapy improves the immune system's ability to fight off bladder cancer, particularly when combined with immunotherapy, according to a study published in Cell Reports Medicine in January.

27 Jan 2024

Atezolizumab plus carboplatin: A winning combination for metastatic triple-negative breast cancer

Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer.

14 Dec 2023

Crown Bioscience launches large-scale organoid panel screening platform for accelerated preclinical oncology drug discovery

Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidXploreTM.

13 Nov 2023

Promising new drug target for triple-negative breast cancer identified

Improving treatments for triple-negative breast cancer (TNBC), an aggressive tumor with very poor prognosis and limited therapeutic targets, has been challenging.

30 Oct 2023

New course of treatment with existing drugs for cervical cancer reduces risk of death by 35%

A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH.

25 Oct 2023

Short course of induction chemotherapy can reduce cervical cancer relapse and death by 35%

The INTERLACE phase III trial, funded by Cancer Research UK and UCL Cancer Trials Centre, assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could reduce the rate of relapse and death among patients with locally advanced cervical cancer.

22 Oct 2023